Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin, on day one after the innovative blockbuster drug from Boehringer Ingelheim (BI) went off patent ...
On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...
Earlier this week, German manufacturer Boehringer Ingelheim’s patent to manufacture Empagliflozin, a medication to treat type 2 diabetes mellitus, expired in India. Empagliflozin is sold under ...
All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...
The Black labor movement exhibit, which was developed for Boehringer Ingelheim and discusses the ... “Some of them contributed photos, but the main thing they contributed was their oral history ...